Jinfeng Lou

Tolerability, pharmacokinetics and antiviral activity of rHSA/IFN&agr;2a for the treatment of chronic hepatitis B infection

J. Niu, Xiaojiao Li, Hong Zhang, 2017, British journal of clinical pharmacology.

Bioequivalence of Sarpogrelate in Healthy Chinese Subjects Under Fasting and Fed Conditions: A 4‐Way Replicate Crossover Investigation by a Reference‐Scaled Average Bioequivalence Approach

Bin Liu, Yanhua Ding, Y. Ding, 2018, Clinical pharmacology in drug development.

Clinical evaluation of efficacy, tolerability and pharmacokinetics of yimitasvir phosphate in patients infected with hepatitis C virus

J. Niu, Xiaojiao Li, Hong Zhang, 2018, The Journal of pharmacy and pharmacology.

First-In-Human Study on Pharmacokinetics, Safety, and Tolerability of Single and Multiple Escalating Doses of Hepenofovir, a Novel Hepatic Targeting Prodrug of Tenofovir in Healthy Chinese Subjects

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2022, Frontiers in Pharmacology.

ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, A randomized, placebo-controlled phase Ib/IIa trial

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2023, Nature communications.

Pharmacokinetics, safety, and tolerability of TQC3564, a novel CRTh2 receptor antagonist: report of the first-in-human single- and multiple-dose escalation trials in healthy Chinese subjects

Xiaojiao Li, Hong Zhang, Yanhua Ding, 2022, Expert opinion on investigational drugs.

Safety, pharmacokinetics and pharmacodynamics of a novel γ-aminobutyric acid (GABA) receptor potentiator, HSK3486, in Chinese patients with hepatic impairment

Shiping Ma, Chengluan Xuan, Xiaojiao Li, 2022, Annals of medicine.